Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Communications Biology Année : 2021

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

Résumé

Abstract The success of cancer immunotherapy relies on the induction of an immunoprotective response targeting tumor antigens (TAs) presented on MHC-I molecules. We demonstrated that the splicing inhibitor isoginkgetin and its water-soluble and non-toxic derivative IP2 act at the production stage of the pioneer translation products (PTPs). We showed that IP2 increases PTP-derived antigen presentation in cancer cells in vitro and impairs tumor growth in vivo. IP2 action is long-lasting and dependent on the CD8 + T cell response against TAs. We observed that the antigen repertoire displayed on MHC-I molecules at the surface of MCA205 fibrosarcoma is modified upon treatment with IP2. In particular, IP2 enhances the presentation of an exon-derived epitope from the tumor suppressor nischarin. The combination of IP2 with a peptide vaccine targeting the nischarin-derived epitope showed a synergistic antitumor effect in vivo. These findings identify the spliceosome as a druggable target for the development of epitope-based immunotherapies.

Dates et versions

hal-03396797 , version 1 (22-10-2021)

Identifiants

Citer

Romain Darrigrand, Alison Pierson, Marine Rouillon, Dolor Renko, Mathilde Boulpicante, et al.. Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens. Communications Biology, 2021, 4 (1), ⟨10.1038/s42003-021-01801-2⟩. ⟨hal-03396797⟩
23 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More